Stock HQL ABRDN LIFE SCIENCES INVESTORS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Abrdn Life Sciences Investors

Equities

HQL

US87911K1007

Closed End Funds

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.97 USD +0.15% Intraday chart for Abrdn Life Sciences Investors +1.33% -3.64%
2023 Tekla Life Sciences Investors Insider Bought Shares Worth $125,116, According to a Recent SEC Filing MT
2023 Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund and Tekla Healthcare Investors Approves Election of Rose Dimartino, C. William Maher, Todd Reit and Stephen Bird as New Trustees CI

Valuation

Fiscal Period: September 2017 2018 2019 2020 2021 2022
Capitalization 1 454.7 449.4 343.6 413 505 343.5
Enterprise Value (EV) 1 454.1 449.4 342.5 413.1 515.1 354.6
P/E ratio 6.76 x 16 x -4.97 x 3.41 x 7.95 x -3.35 x
Yield 7.4% 7.98% 9.87% 8.36% 8.03% 10.8%
Capitalization / Revenue 270 x 226 x 141 x 122 x 221 x 114 x
EV / Revenue 270 x 226 x 140 x 122 x 225 x 117 x
EV / EBITDA - - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 0.99 x 0.96 x 0.91 x 0.87 x 0.98 x 0.88 x
Nbr of stocks (in thousands) 21,170 22,008 22,756 23,495 24,279 25,144
Reference price 2 21.48 20.42 15.10 17.58 20.80 13.66
Announcement Date 12/5/17 12/4/18 12/5/19 12/4/20 12/3/21 12/7/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2017 2018 2019 2020 2021 2022
Net sales 1 1.682 1.986 2.441 3.392 2.286 3.019
EBITDA - - - - - -
EBIT 1 -3.879 -3.607 -2.879 -2.115 -4.139 -2.99
Operating Margin -230.58% -181.64% -117.97% -62.35% -181.04% -99.05%
Earnings before Tax (EBT) 1 68.56 28.66 -70.48 123.1 64.53 -104.6
Net income 1 68.56 28.66 -70.48 123.1 64.53 -104.6
Net margin 4,075.45% 1,443.44% -2,887.77% 3,628.14% 2,822.5% -3,464.88%
EPS 2 3.178 1.279 -3.041 5.152 2.616 -4.073
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 1.590 1.630 1.490 1.470 1.670 1.470
Announcement Date 12/5/17 12/4/18 12/5/19 12/4/20 12/3/21 12/7/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - 0.01 10 11.1
Net Cash position 1 0.62 0 1.12 - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) 15.6% 6.09% -16.4% 28.4% 12.8% -22.7%
ROA (Net income/ Total Assets) -0.55% -0.48% -0.42% -0.3% -0.51% -0.39%
Assets 1 -12,528 -6,019 16,950 -40,558 -12,703 26,562
Book Value Per Share 2 21.60 21.20 16.60 20.20 21.20 15.50
Cash Flow per Share 2 0.0300 0 0.0500 - 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 12/5/17 12/4/18 12/5/19 12/4/20 12/3/21 12/7/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Closed End Funds

1st Jan change Capi.
ABRDN LIFE SCIENCES INVESTORS Stock Abrdn Life Sciences Investors
-3.64% 355M
ARES CAPITAL CORPORATION Stock Ares Capital Corporation
+3.74% 12.61B
PERSHING SQUARE HOLDINGS, LTD. Stock Pershing Square Holdings, Ltd.
+5.50% 9.01B
FS KKR CAPITAL CORP. Stock FS KKR Capital Corp.
-3.20% 5.41B
SPROTT PHYSICAL URANIUM TRUST FUND Stock Sprott Physical Uranium Trust Fund
+2.44% 5.25B
PIMCO DYNAMIC INCOME FUND Stock PIMCO Dynamic Income Fund
+5.63% 5.19B
SPROTT PHYSICAL SILVER TRUST Stock Sprott Physical Silver Trust
+14.36% 4.48B
SPROTT PHYSICAL GOLD AND SILVER TRUST Stock Sprott Physical Gold and Silver Trust
+16.67% 4.44B
MACQUARIE KOREA INFRASTRUCTURE FUND Stock Macquarie Korea Infrastructure Fund
+1.53% 4B
3I INFRASTRUCTURE PLC Stock 3i Infrastructure plc
+1.56% 3.75B
Closed End Funds
  1. Stock Market
  2. Equities
  3. HQL Stock
  4. Financials Abrdn Life Sciences Investors